Development, safety, and efficacy of biosimilar adalimumab: the data so far

References

• Annese V, Vecchi M; on behalf of the Italian Group for the Study of IBD (IG-IBD). Use of biosimilars in inflammatory bowel disease: statements of the Italian Group for Inflammatory Bowel Disease. Progress report. Dig Liver Dis. 2014;46:963–968.
   PubMedGoogle Scholar
• Rinaudo-Gaujous M, Paul S, Tedesco ED, Genin C, Roblin X, Peyrin-Biroulet L. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther. 2013;38:914–924.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). 2012. Available from: http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500020062. Accessed January 18, 2013.
   Google Scholar
• European Medicines Agency. Human medicines – biosimilars. 2013. Available from: http://www.ema.europa.eu/ema/. Accessed January 18, 2013.
   Google Scholar
• McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs. 2011;3(2):209–217.
   PubMed Web of Science ®Google Scholar
• McCamish M, Woollett G. The rise of the biosimilar. Expert Rev Clin Pharmacol. 2012;5:597–599.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8:226–234.
   PubMed Web of Science ®Google Scholar
• Misra M. Biosimilars: current perspectives and future implications. Indian J Pharmacol. 2012;44:12–14.
   Web of Science ®Google Scholar
• Gecse KB, Khanna R, Van den Brink GR, et al. Biosimilars in IBD: hope or expectation? Gut. 2013;62(6):803–807.
   Web of Science ®Google Scholar
• Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42:177–183.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of anti-tumor necrosis factor agents in Crohn’s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644–653.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–838.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780–787.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–265. e1–e3.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard M-A. Adalimumab induction therapy for ulcerative colitis within tolerance or lost response to infliximab: an open-label study. World J Gastroenterol. 2007;13:2328–2332.
   PubMed Web of Science ®Google Scholar
• Oussalah A, Laclotte C, Chevaux JB, Bensenane M, Babouri A, Serre AA. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther. 2008;28:966–972.
   PubMed Web of Science ®Google Scholar
• Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009;15:1302–1307.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Van Assche G, Reinisch W, et al. Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe ulcerative colitis. J Crohns Colitis. 2011;5:68.
   Google Scholar
• Evaluate™. KFDA Approves Remsima(TM) (infliximab), the World’s First Antibody Biosimilar [press release]. Celltrion, Johnson & Johnson; 2012 [July 23]. Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=320129. Accessed December 29, 2015.
   Google Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620.
   PubMed Web of Science ®Google Scholar
• Health Canada. Summary Basis of Decision (SBD) for Inflectra. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_inflectra_159493-eng.php. Accessed October 15, 2014.
   Google Scholar
• Cadila Healthcare Ltd. Zydus Launches World’s First Biosimilar of Adalimumab [press release]. Zydus Cadila. Available at: http://exemptia.com/zydus-launches-worlds-first-biosimilar-of-adalimumab-2/. Accessed October 16, 2015.
   Google Scholar
• Bandyopadhyay S, Mahajan M, Mehta T, et al. Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197. Biosimilars. 2015:5:1–18.
   Google Scholar
• Clinical Trial Registry India. New Delhi: Indian National Institute of Medical Statistics (NIMS). Available from: http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=7595&EncHid=&userName=adalimumab. Accessed October 16, 2015.
   Google Scholar
• CTRI/2013/10/004040. Medicines Agency. London: Medicines Agency. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000109.jsp. Accessed October 16, 2015.
   Google Scholar
• Central Drugs Standard Control Organization. Director General of Health Services, Ministry of Health and Family Welfare, Government of India. Available from: http://www.cdsco.nic.in/. Accessed October 16, 2015.
   Google Scholar
• NCT02016105. ClinicalTrials.gov. Bethesda, MD: US National Institutes of Health. Available from: https://clinicaltrials.gov/ct2/show/NCT02016105?term=GP+2017&rank=1. Accessed October 16, 2015.
   Google Scholar
• CT Number: 2013-000747-11. EU Clinical Trials Register Service. London: European Medicines Agency. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=GP2017. Accessed October 16, 2015.
   Google Scholar
• NCT01970475. ClinicalTrials.gov. Bethesda, MD: US National Institutes of Health. Available from: https://clinicaltrials.gov/ct2/show/NCT01970475?term=ABP501&rank=3. Accessed October 16, 2015.
   Google Scholar
• CT Number: 2013-004654-13. EU Clinical Trials Register Service. London: European Medicines Agency. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=ABP+501. Accessed October 16, 2015.
   Google Scholar
• NCT01970488. ClinicalTrials.gov. Bethesda, MD: US National Institutes of Health. Available from: https://clinicaltrials.gov/ct2/show/NCT01970488?term=ABP501&rank=2. Accessed October 16, 2015.
   Google Scholar
• NCT02114931. ClinicalTrials.gov. Bethesda, MD: US National Institutes of Health. Available from: https://clinicaltrials.gov/ct2/show/NCT02114931?term=ABP501&rank=1. Accessed October 16, 2015.
   Google Scholar
• Oncobiologics™. ONS-3010 (Humira^®/Adalimumab Biosimilar) Meets Primary Endpoints In First Clinical Study [press release]. Cranbury, NJ: Oncobiologics™; 2015 [February 12]. Available from: http://oncobiologics.com/as_press-releases&recordID=18667. Accessed December 29, 2015.
   Google Scholar
• NCT02137226. ClinicalTrials.gov. Bethesda, MD: US National Institutes of Health. Available from: https://clinicaltrials.gov/ct2/show/NCT02137226?term=Boehringer+Ingelheim+adalimumab&rank=3. Accessed December 29, 2015.
   Google Scholar